ES2120402T3 - Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar. - Google Patents

Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.

Info

Publication number
ES2120402T3
ES2120402T3 ES88310942T ES88310942T ES2120402T3 ES 2120402 T3 ES2120402 T3 ES 2120402T3 ES 88310942 T ES88310942 T ES 88310942T ES 88310942 T ES88310942 T ES 88310942T ES 2120402 T3 ES2120402 T3 ES 2120402T3
Authority
ES
Spain
Prior art keywords
salt
lipase
biliar
procedures
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310942T
Other languages
English (en)
Inventor
Jordan J N Tang
Chi-Sun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2120402T3 publication Critical patent/ES2120402T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1216—Other enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/801—Pediatric

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

COMPOSICIONES DE DIETAS, ESPECIALMENTE FORMULAS PARA NIÑOS A BASE DE LECHE DE VACA, SE FORTALECEN CON LIPASA ACTIVADA CON SAL DE BILIS. SE PROPORCIONAN METODOS PARA ALIMENTAR RECIEN NACIDOS Y NIÑOS PREMATUROS, QUE INCLUYEN LA ADMINISTRACION DE LIPASA ACTIVADA POR SAL DE BILIS PARA AUMENTAR LA DIGESTION DE LA GRASA Y CON ELLO LA VELOCIDAD DE CRECIMIENTO.. DE MODO SIMILAR, SE PROPORCIONA UN METODO PARA TRATAR SUJETOS CON INADECUADA PRODUCCION DE ENZIMA PANCREATICO, POR ADMINISTRACION DE LIPASA ACTIVADA CON SAL DE BILIS, JUNTO CON INGESTION DE GRASAS.
ES88310942T 1987-11-19 1988-11-18 Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar. Expired - Lifetime ES2120402T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/122,410 US4944944A (en) 1987-11-19 1987-11-19 Dietary compositions and methods using bile salt-activated lipase

Publications (1)

Publication Number Publication Date
ES2120402T3 true ES2120402T3 (es) 1998-11-01

Family

ID=22402581

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93203480T Expired - Lifetime ES2152941T3 (es) 1987-11-19 1988-11-18 Utilizacion de lipasa activada de sal biliar como suplemento dietetico.
ES88310942T Expired - Lifetime ES2120402T3 (es) 1987-11-19 1988-11-18 Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES93203480T Expired - Lifetime ES2152941T3 (es) 1987-11-19 1988-11-18 Utilizacion de lipasa activada de sal biliar como suplemento dietetico.

Country Status (7)

Country Link
US (1) US4944944A (es)
EP (2) EP0317355B1 (es)
JP (2) JP2592939B2 (es)
AT (2) ATE167982T1 (es)
DE (2) DE3856214T2 (es)
ES (2) ES2152941T3 (es)
GR (1) GR3035093T3 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200183A (en) * 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5008120A (en) * 1989-07-21 1991-04-16 Snow Brand Milk Products Co., Ltd. Method of preparing iron-fortified beverage
US5173408A (en) * 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
JP2808166B2 (ja) * 1990-04-26 1998-10-08 雪印乳業株式会社 鉄強化飲料の製造方法
US5186961A (en) * 1991-03-15 1993-02-16 North Carolina State University Method and composition for maintaining animals on a keratin-containing diet
US5169666A (en) * 1991-11-14 1992-12-08 The United States Of America As Represented By The Secretary Of Agriculture Preparation of simulated human milk protein by low temperature microfiltration
US5902617A (en) * 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
IS4130A (is) * 1993-03-01 1994-09-02 Ab Astra Ný fjölpeptíð
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
AU750891B2 (en) 1996-12-06 2002-08-01 Aventis Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
WO1999048372A1 (en) 1998-03-23 1999-09-30 General Mills, Inc. Encapsulation of components into edible products
US6399090B1 (en) * 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
DE69939900D1 (de) * 1998-06-05 2008-12-24 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
AU5032600A (en) * 1999-05-19 2001-12-03 Barnes-Jewish Hospital Enhanced triglyceride digestion in a deficiency of bile salts
EP1059041A1 (en) * 1999-06-07 2000-12-13 Universiteit Gent The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
EP1539222A1 (en) * 2002-07-02 2005-06-15 The Regents Of The University Of California Treatment for eye disorder
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
CA2515583C (en) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS
AR059692A1 (es) * 2007-03-01 2008-04-23 Adriana Fernandez Alimento de alto contenido calorico y de facil digestion
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
AU2010362575A1 (en) 2010-10-21 2013-04-11 Swedish Orphan Biovitrum Ab (Publ) Method to increase the absorption of unsaturated fatty acids by human infants
JP5850940B2 (ja) 2010-10-21 2016-02-03 スウェディッシュ オーファン バイオビトラム パブリーク アクチエボラグ ヒト乳児の発育速度を増大させる方法
IL313986B1 (en) 2012-02-17 2026-05-01 Alcresta Inc Methods, compositions and devices for supplying dietary fatty acid needs
GB201501081D0 (en) * 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
AU2017237164A1 (en) 2016-03-24 2018-10-11 Nutrinia Ltd. Use of insulin for promoting gastric emptying
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA662815A (en) * 1963-05-07 G. Farnham Merle Treatment for "scours" in mammals
US3256150A (en) * 1964-04-20 1966-06-14 Dairyland Food Lab Method for treating malabsorption syndrome
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
JPS5017559B2 (es) * 1972-09-20 1975-06-21
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2638089C2 (de) * 1976-08-24 1985-04-25 Degussa Ag, 6000 Frankfurt Lipase-Präparate mit verbesserter Wirkung
GB1571877A (en) * 1978-04-24 1980-07-23 Meito Sangyo Kk Microbial lipase and its preparation
JPS6047858B2 (ja) * 1978-09-20 1985-10-24 田村 輝 温浴用水製造装置
DE2923279C2 (de) * 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
DE3586122D1 (de) * 1985-01-09 1992-07-02 Genencor Inc Ueberfuehrung von exogenen stoffen in kaesebruch.
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase

Also Published As

Publication number Publication date
EP0605913A1 (en) 1994-07-13
EP0605913B1 (en) 2000-10-25
DE3856214D1 (de) 1998-08-13
EP0317355A3 (en) 1991-07-17
JPH06315347A (ja) 1994-11-15
DE3856435T2 (de) 2001-03-29
JPH01231848A (ja) 1989-09-18
ES2152941T3 (es) 2001-02-16
JP2592939B2 (ja) 1997-03-19
HK1023031A1 (en) 2000-08-25
EP0317355B1 (en) 1998-07-08
ATE167982T1 (de) 1998-07-15
GR3035093T3 (en) 2001-03-30
EP0317355A2 (en) 1989-05-24
DE3856435D1 (de) 2000-11-30
HK1012213A1 (en) 1999-07-30
DE3856214T2 (de) 1998-12-17
ATE197127T1 (de) 2000-11-15
US4944944A (en) 1990-07-31

Similar Documents

Publication Publication Date Title
GR3035093T3 (en) Use of bile salt-activated lipase as dietary supplement.
DE3570362D1 (en) Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity
AU628662B2 (en) Dietary supplement and method of minimizing effects of infection through diet
US6699496B1 (en) Enzyme in a dosage form for oral use in mammals, enzyme-containing food material and method for administering the enzyme in a dosage form
GB9519661D0 (en) Fatty acid treatment
JPS6466118A (en) Free fatty acid for treating or preventing chronic articular rheumatism
IE891819L (en) Essential fatty acid compositions
DK0764405T3 (da) Ernæringspræparat
PL338219A1 (en) Therapeutic and dietary compositions containing necessary unsaturated fatty acids and biologically active disulphides
CA2159058A1 (en) Inhibition of helicobacter
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
ATE212194T1 (de) Nahrungsprodukt zur behandlung der ulzerativen kolitis sowie verwendung desselben
Sarles et al. Alcoholic pancreatitis
IE791002L (en) Composition for total parenteral nutrition
AU7438287A (en) Omega-3 fatty acid aided reduction of cyclosporin mephrotoxicity
EP0315113A3 (en) Inner esters of gangliosides with analgesic-antiinflammatory activity
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
Borel et al. Gastric lipase: evidence of an adaptive response to dietary fat in the rabbit
MY131357A (en) Fatty acid treatment
GB8916734D0 (en) Pharmaceutical and dietary uses of fatty acids
AU1489688A (en) Omega-3 fatty acids in traumatic injury treatment
Bates Racially determined abnormal essential fatty acid and prostaglandin metabolism and food allergies linked to autoimmune, inflammatory, and psychiatric disorders among coastal British Columbia indians
KR880010762A (ko) 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
Bloor Handbook of nutrition: III: role of fat in the diet
FR2351658A1 (fr) Medicament pour le traitement d'hyperlipoproteinemies primaires et secondaires

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 317355

Country of ref document: ES